Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response (Q79165387)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17012049%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

title

Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17012049%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

Robin L Jones

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17012049%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Ian E Smith

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17012049%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

publication date

1 October 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17012049%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

20 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17012049%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17012049%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17012049%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

869-874

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17012049%20AND%20SRC:MED&resulttype=core&format=json

Is there still a role for neoadjuvant therapy in breast cancer?

20 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970906-8

7 January 2021

10.1016/S1470-2045(06)70906-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17012049%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference